Bluejay Diagnostics (BJDX) links director options to FDA nod
Rhea-AI Filing Summary
Bluejay Diagnostics, Inc. (BJDX) reported that director Fred S. Zeidman received a grant of 100,000 stock options on 2026-08-17. These options have an exercise price of $2.075 per share and expire on 2031-08-17. They vest on the first anniversary of the grant date and are not exercisable unless and until the U.S. Food and Drug Administration grants clearance or approval of Bluejay’s Symphony IL-6 point-of-care testing device. Following this grant, Zeidman holds 100,000 options directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
ZEIDMAN FRED S
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 100,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 100,000 shares (Direct)
Footnotes (1)
- F1. Represents out-of-the-money stock options that vest and become exercisable for $2.075 per share on the first anniversary of the grant date, provided, however, that the options shall not be exercisable unless and until the U.S. Food and Drug Administration shall have granted clearance or approval of the issuer's Symphony IL-6 point-of-care testing device.
Key Figures
Options granted: 100,000 options
Exercise price: $2.075 per share
Expiration date: 2031-08-17
+2 more
5 metrics
Options granted
100,000 options
Stock Option (Right to Buy) granted to director on 2026-08-17
Exercise price
$2.075 per share
Conversion or exercise price for the granted stock options
Expiration date
2031-08-17
Expiration of the granted stock options
Underlying shares
100,000 shares
Common Stock underlying the granted options
Vesting timing
First anniversary of grant date
Time-based vesting condition for the options
Key Terms
out-of-the-money stock options, point-of-care testing device, U.S. Food and Drug Administration
3 terms
out-of-the-money stock options financial
"Represents out-of-the-money stock options that vest and become exercisable"
point-of-care testing device medical
"approval of the issuer's Symphony IL-6 point-of-care testing device"
U.S. Food and Drug Administration regulatory
"unless and until the U.S. Food and Drug Administration shall have granted"
The U.S. Food and Drug Administration is the federal agency that evaluates and enforces safety, effectiveness and labeling standards for medicines, medical devices, vaccines, food and related products before they reach consumers. For investors it matters because FDA approvals, warnings or recalls determine whether a product can be sold, how quickly it reaches the market and how costly compliance will be—changes that directly affect a company’s revenue, costs and stock value.
FAQ
What did BJDX director Fred S. Zeidman acquire in this Form 4?
Fred S. Zeidman was granted 100,000 stock options for Bluejay Diagnostics, Inc. (BJDX). The options relate to Common Stock and represent a compensation-related acquisition rather than an open-market purchase.
What is the exercise price and term of the new BJDX options?
The granted options have an exercise price of $2.075 per share and expire on 2031-08-17. This gives the holder the right to buy BJDX common shares at that price if vesting and exercisability conditions are satisfied.
When do Fred S. Zeidman’s BJDX options vest and become exercisable?
The options vest and become exercisable on the first anniversary of the grant date. However, they are not exercisable unless the U.S. Food and Drug Administration grants clearance or approval of Bluejay’s Symphony IL-6 point-of-care testing device.
What regulatory milestone affects exercisability of these BJDX options?
Exercisability depends on FDA clearance or approval of Bluejay’s Symphony IL-6 point-of-care testing device. Until this regulatory milestone occurs, the options, even if vested by time, cannot be exercised.
How many BJDX options does Fred S. Zeidman hold after this transaction?
After this grant, Fred S. Zeidman holds 100,000 stock options directly. These options are currently described as out-of-the-money, with vesting and exercisability both subject to time and FDA-related conditions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
